Clinical Trial Update: Ramucirumab/Paclitaxel as Second-line Treatment in Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma With Integrative Genomic Analysis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ramucirumab plus paclitaxel as second-line therapy for metastatic gastric or gastroesophageal junction adenocarcinoma with integrative …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Adenocarcinoma
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• PACLITAXEL (PACLITAXEL)
• Ramucirumab (ramucirumab)

Snippet

Sponsor: Samsung Medical Center | Conditions: Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Phase 2 | Status: COMPLETED